Phase ll Study of Pirfenidone in Patients With RAILD (TRAIL1)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2016
The purpose of this study is to to assess the safety and tolerability of pirfenidone 2403 mg/day for the treatment of RA-associated interstitial lung disease.
Epistemonikos ID: 9ceec73e94ba4b6653ad098ee60346fe5471b1ea
First added on: Mar 23, 2022